120 related articles for article (PubMed ID: 24157365)
1. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.
Futatsugi K; Piotrowski DW; Casimiro-Garcia A; Robinson S; Sammons M; Loria PM; Banker ME; Petersen DN; Schmidt NJ
Bioorg Med Chem Lett; 2013 Dec; 23(23):6239-42. PubMed ID: 24157365
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
Hasui T; Ohra T; Ohyabu N; Asano K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2013 Oct; 21(19):5983-94. PubMed ID: 23958516
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.
Nordqvist A; O'Mahony G; Fridén-Saxin M; Fredenwall M; Hogner A; Granberg KL; Aagaard A; Bäckström S; Gunnarsson A; Kaminski T; Xue Y; Dellsén A; Hansson E; Hansson P; Ivarsson I; Karlsson U; Bamberg K; Hermansson M; Georgsson J; Lindmark B; Edman K
ChemMedChem; 2017 Jan; 12(1):50-65. PubMed ID: 27897427
[TBL] [Abstract][Full Text] [Related]
4. Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
Baker J; Bingham M; Blackburn-Munro R; Cai J; Craighead M; Gilfillan R; Goan K; Jaap D; Milne R; Morphy JR; Napier S; Presland J; Spinks G; Thomson F
Bioorg Med Chem Lett; 2011 Jun; 21(12):3603-7. PubMed ID: 21601454
[TBL] [Abstract][Full Text] [Related]
5. Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.
Lotesta SD; Marcus AP; Zheng Y; Leftheris K; Noto PB; Meng S; Kandpal G; Chen G; Zhou J; McKeever B; Bukhtiyarov Y; Zhao Y; Lala DS; Singh SB; McGeehan GM
Bioorg Med Chem; 2016 Mar; 24(6):1384-91. PubMed ID: 26897089
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
[TBL] [Abstract][Full Text] [Related]
8. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
10. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Casimiro-Garcia A; Piotrowski DW; Ambler C; Arhancet GB; Banker ME; Banks T; Boustany-Kari CM; Cai C; Chen X; Eudy R; Hepworth D; Hulford CA; Jennings SM; Loria PM; Meyers MJ; Petersen DN; Raheja NK; Sammons M; She L; Song K; Vrieze D; Wei L
J Med Chem; 2014 May; 57(10):4273-88. PubMed ID: 24738581
[TBL] [Abstract][Full Text] [Related]
11. Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Martín-Martínez M; Pérez-Gordillo FL; Álvarez de la Rosa D; Rodríguez Y; Gerona-Navarro G; González-Muñiz R; Zhou MM
J Med Chem; 2017 Apr; 60(7):2629-2650. PubMed ID: 28051871
[TBL] [Abstract][Full Text] [Related]
12. Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.
Piotrowski DW; Futatsugi K; Casimiro-Garcia A; Wei L; Sammons MF; Herr M; Jiao W; Lavergne SY; Coffey SB; Wright SW; Song K; Loria PM; Banker ME; Petersen DN; Bauman J
J Med Chem; 2018 Feb; 61(3):1086-1097. PubMed ID: 29300474
[TBL] [Abstract][Full Text] [Related]
13. N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
van Loevezijn A; Venhorst J; Iwema Bakker WI; de Korte CG; de Looff W; Verhoog S; van Wees JW; van Hoeve M; van de Woestijne RP; van der Neut MA; Borst AJ; van Dongen MJ; de Bruin NM; Keizer HG; Kruse CG
J Med Chem; 2011 Oct; 54(20):7030-54. PubMed ID: 21866910
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
Scott JD; Miller MW; Li SW; Lin SI; Vaccaro HA; Hong L; Mullins DE; Guzzi M; Weinstein J; Hodgson RA; Varty GB; Stamford AW; Chan TY; McKittrick BA; Greenlee WJ; Priestley T; Parker EM
Bioorg Med Chem Lett; 2009 Nov; 19(21):6018-22. PubMed ID: 19800231
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Collin M; Niemann F; Jaisser F
Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
[TBL] [Abstract][Full Text] [Related]
17. Alpha-methyltryptamine sulfonamide derivatives as novel glucocorticoid receptor ligands.
Marshall DR; Rodriguez G; Thomson DS; Nelson R; Capolina A
Bioorg Med Chem Lett; 2007 Jan; 17(2):315-9. PubMed ID: 17118655
[TBL] [Abstract][Full Text] [Related]
18. Substituted phenyl as a steroid A-ring mimetic: providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands.
DiSalvo D; Kuzmich D; Bentzien J; Regan J; Kukulka A; Fadra-Khan T; Nelson R; Harcken C; Thomson D; Nabozny G
Bioorg Med Chem Lett; 2013 Dec; 23(24):6645-9. PubMed ID: 24239189
[TBL] [Abstract][Full Text] [Related]
19. Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists.
Hennessy EJ; Grewal G; Byth K; Kamhi VM; Li D; Lyne P; Oza V; Ronco L; Rooney MT; Saeh JC; Su Q
Bioorg Med Chem Lett; 2015; 25(10):2041-5. PubMed ID: 25890801
[TBL] [Abstract][Full Text] [Related]
20. Lead identification and structure-activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Miah AH; Copley RC; O'Flynn D; Percy JM; Procopiou PA
Org Biomol Chem; 2014 Mar; 12(11):1779-92. PubMed ID: 24515101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
